[Efficaccy of probiotic in the treatment of small intestinal bacterial overgrowth. Systematic review and meta-analysis].

Q4 Medicine
Sebastian Fernando Niño, Marco Santiesteban, Gloria Muñoz Valencia
{"title":"[Efficaccy of probiotic in the treatment of small intestinal bacterial overgrowth. Systematic review and meta-analysis].","authors":"Sebastian Fernando Niño, Marco Santiesteban, Gloria Muñoz Valencia","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Conventional management of small intestinal bacterial overgrowth (SIBO) involves intraluminal-action antibiotics. Controversially, probiotics are used to optimize outcomes, but this therapeutic intervention is understudied.</p><p><strong>Objective: </strong>To evaluate the efficacy of probiotics in the treatment of small intestinal bacterial overgrowth. Materials and methos: A search was conducted using relevant terms guided by a documentalist in CENTRAL, MEDLINE, and EMBASE, LILACS, conference proceedings, the International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov, in English or Spanish, up to January 2023. The search aimed to identify studies evaluating the effectiveness of probiotics in small intestinal bacterial overgrowth. Controlled trials of probiotics compared to placebo or other interventions (antibiotics) for symptom control and normalization of hydrogen breath test in adult patients with small intestinal bacterial overgrowth were included. Two authors independently assessed and extracted data. Information on methods, participants, interventions, and outcomes (resolution of SIBO by hydrogen breath test, symptom control) was collected. When appropriate, risk ratios (OR) with 95% confidence intervals (CI) were calculated. Study quality was evaluated using the Cochrane Risk of Bias Assessment Tool.</p><p><strong>Results: </strong>A total of 18 clinical trials were found, including one case-control study, two crossover trials, and one single-arm clinical trial. Out of these, 14 clinical trials had a control group, of which 9 were randomized, collecting information from 496 patients treated with probiotics and 480 controls. Among them, 6 clinical trials compared probiotics (n=122) against placebo (n=104). Due to lack of uniformity in outcome reporting, only 3 of these studies were included in the meta-analysis, revealing a favorable effect of probiotics in resolving SIBO by hydrogen breath test (OR=0.3, 95% CI, 0.3-1.0). The studies showed high heterogeneity and a high risk of bias.</p><p><strong>Conclusions: </strong>Using the GRADE methodology, we found low-quality clinical evidence in favor of using probiotics compared to placebo for the resolution of SIBO.</p>","PeriodicalId":35807,"journal":{"name":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Conventional management of small intestinal bacterial overgrowth (SIBO) involves intraluminal-action antibiotics. Controversially, probiotics are used to optimize outcomes, but this therapeutic intervention is understudied.

Objective: To evaluate the efficacy of probiotics in the treatment of small intestinal bacterial overgrowth. Materials and methos: A search was conducted using relevant terms guided by a documentalist in CENTRAL, MEDLINE, and EMBASE, LILACS, conference proceedings, the International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov, in English or Spanish, up to January 2023. The search aimed to identify studies evaluating the effectiveness of probiotics in small intestinal bacterial overgrowth. Controlled trials of probiotics compared to placebo or other interventions (antibiotics) for symptom control and normalization of hydrogen breath test in adult patients with small intestinal bacterial overgrowth were included. Two authors independently assessed and extracted data. Information on methods, participants, interventions, and outcomes (resolution of SIBO by hydrogen breath test, symptom control) was collected. When appropriate, risk ratios (OR) with 95% confidence intervals (CI) were calculated. Study quality was evaluated using the Cochrane Risk of Bias Assessment Tool.

Results: A total of 18 clinical trials were found, including one case-control study, two crossover trials, and one single-arm clinical trial. Out of these, 14 clinical trials had a control group, of which 9 were randomized, collecting information from 496 patients treated with probiotics and 480 controls. Among them, 6 clinical trials compared probiotics (n=122) against placebo (n=104). Due to lack of uniformity in outcome reporting, only 3 of these studies were included in the meta-analysis, revealing a favorable effect of probiotics in resolving SIBO by hydrogen breath test (OR=0.3, 95% CI, 0.3-1.0). The studies showed high heterogeneity and a high risk of bias.

Conclusions: Using the GRADE methodology, we found low-quality clinical evidence in favor of using probiotics compared to placebo for the resolution of SIBO.

[益生菌治疗小肠细菌过度生长的疗效。系统回顾和荟萃分析]。
导言:小肠细菌过度生长(SIBO)的传统治疗方法包括腔内作用抗生素。有争议的是,益生菌被用来优化治疗效果,但这种治疗干预措施的研究还不充分:目的:评估益生菌治疗小肠细菌过度生长的疗效。材料和方法在文献专家的指导下,使用相关术语在 CENTRAL、MEDLINE 和 EMBASE、LILACS、会议论文集、国际临床试验注册平台 (ICTRP) 和 ClinicalTrials.gov 中进行了检索,检索语言为英语或西班牙语,检索期截至 2023 年 1 月。该检索旨在确定评估益生菌对小肠细菌过度生长的有效性的研究。研究纳入了益生菌与安慰剂或其他干预措施(抗生素)对小肠细菌过度生长成人患者症状控制和氢气呼气试验正常化的对照试验。两位作者独立评估并提取数据。收集了有关方法、参与者、干预措施和结果(通过氢气呼气试验解决 SIBO、症状控制)的信息。适当时,计算风险比 (OR) 和 95% 置信区间 (CI)。研究质量采用 Cochrane 偏倚风险评估工具进行评估:共发现 18 项临床试验,包括一项病例对照研究、两项交叉试验和一项单臂临床试验。其中,14 项临床试验设有对照组,其中 9 项为随机试验,收集了 496 名接受益生菌治疗的患者和 480 名对照组患者的信息。其中,6 项临床试验将益生菌(122 人)与安慰剂(104 人)进行了比较。由于结果报告缺乏统一性,只有其中 3 项研究被纳入荟萃分析,结果显示益生菌对通过氢气呼气试验解决 SIBO 有有利影响(OR=0.3,95% CI,0.3-1.0)。这些研究显示出高度异质性和高偏倚风险:采用 GRADE 方法,我们发现了支持使用益生菌治疗 SIBO 的低质量临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
49
期刊介绍: La REVISTA DE GASTROENTEROLOGíA DEL PERÚ, es la publicación oficial de la Sociedad de Gastroenterología del Perú que publica artículos originales, artículos de revisión, reporte de casos, cartas e información general de la especialidad; dirigido a los profesionales de la salud con especial interés en la gastroenterología. La Revista de Gastroenterología del Perú es una publicación de periodicidad trimestral y tiene como objetivo la publicación de artículos científicos inéditos en el campo de la gastroenterología, proporcionando información actualizada y relevante de la especialidad y áreas afines. La Revista de Gastroenterología del Perú publica artículos en dos idiomas, español e inglés, a texto completo en la versión impresa yelectrónica. Los artículos científicos son sometidos a revisores o árbitros nacionales e internacionales, especialistas que opinan bajo la modalidad de doble ciego y de manera anónima sobre la calidad y validez de los mismos. El número de revisores depende del tipo de artículo, dos revisores como mínimo para artículos originales y uno como mínimo para otros tipos de artículos.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信